Efficacy and safety of oral tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphomas: A systematic review and proportionality meta-analysis.

Authors: Haris Mumtaz Malik, Beenish Sabir, Shahroz Ansar, Shazia Hashim, Adnan Bhat, Javed Iqbal, Allahdad Khan, Muhammad Ibrahim, Maria Qadri, Noor ul ain Saleem, Shamikha Cheema, Muhammad Riyyan

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e19045

Source: Full article

---

Abstract

e19045